1
|
Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczyñski GM, Głodkowska E, Mrówka P, Issat T, Dulak J, Józkowicz A, Waś H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stokłosa T, Jakóbisiak M, Gołąb J. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 2006; 25:3365-74. [PMID: 16462769 PMCID: PMC1538962 DOI: 10.1038/sj.onc.1209378] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Photodynamic therapy is a promising antitumor treatment modality approved for the management of both early and advanced tumors. The mechanisms of its antitumor action include generation of singlet oxygen and reactive oxygen species that directly damage tumor cells and tumor vasculature. A number of mechanisms seem to be involved in the protective responses to PDT that include activation of transcription factors, heat shock proteins, antioxidant enzymes and antiapoptotic pathways. Elucidation of these mechanisms might result in the design of more effective combination strategies to improve the antitumor efficacy of PDT. Using DNA microarray analysis to identify stress-related genes induced by Photofrin-mediated PDT in colon adenocarcinoma C-26 cells, we observed a marked induction of heme oxygenase-1 (HO-1). Induction of HO-1 with hemin or stable transfection of C-26 with a plasmid vector encoding HO-1 increased resistance of tumor cells to PDT-mediated cytotoxicity. On the other hand, zinc (II) protoporphyrin IX, an HO-1 inhibitor, markedly augmented PDT-mediated cytotoxicity towards C-26 and human ovarian carcinoma MDAH2774 cells. Neither bilirubin, biliverdin nor carbon monoxide, direct products of HO-1 catalysed heme degradation, was responsible for cytoprotection. Importantly, desferrioxamine, a potent iron chelator significantly potentiated cytotoxic effects of PDT. Altogether our results indicate that HO-1 is involved in an important protective mechanism against PDT-mediated phototoxicity and administration of HO-1 inhibitors might be an effective way to potentiate antitumor effectiveness of PDT.
Collapse
Affiliation(s)
- D Nowis
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - M Legat
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - T Grzela
- Department of Histology and Embryology, Center of Biostructure Research; The Medical University of Warsaw, Warsaw, Poland
| | - J Niderla
- Department of Histology and Embryology, Center of Biostructure Research; The Medical University of Warsaw, Warsaw, Poland
| | - E Wilczek
- Department of Pathology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - GM Wilczyñski
- Department of Pathology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - E Głodkowska
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - P Mrówka
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - T Issat
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - J Dulak
- Department of Medical Biotechnology, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland
| | - A Józkowicz
- Department of Medical Biotechnology, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland
| | - H Waś
- Department of Medical Biotechnology, Faculty of Biotechnology, Jagiellonian University, Krakow, Poland
| | - M Adamek
- Center for Laser Diagnostics and Therapy, Chair and Clinic of Internal Diseases and Physical Medicine, Silesian Medical University, Bytom, Poland
| | - A Wrzosek
- Department of Muscle Biochemistry, M Nencki Institute of Experimental Biology, Warsaw, Poland
| | - S Nazarewski
- Department of General and Vascular Surgery and Transplantation, The Medical University of Warsaw, Warsaw, Poland
| | - M Makowski
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - T Stokłosa
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - M Jakóbisiak
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| | - J Gołąb
- Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
2
|
Stokłosa T, Gołab J, Wójcik C, Włodarski P, Jalili A, Januszko P, Giermasz A, Wilczyński GM, Pleban E, Marczak M, Wilk S, Jakóbisiak M. Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis 2004; 9:193-204. [PMID: 15004516 DOI: 10.1023/b:appt.0000018801.59062.1d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Inhibition of the proteasome, a multicatalytic proteinase complex, is an attractive approach to cancer therapy. Here we report that a selective inhibitor of the chymotrypsin-like activity of the proteasome, PSI (N-benzyloxycarbonyl-Ile-Glu(O-t-butyl)-Ala-leucinal) may inhibit growth of solid tumors not only through apoptosis induction, but also indirectly--through inhibition of angiogenesis. Two murine tumors: colon adenocarcinoma (C-26) and Lewis lung carcinoma (3LL) were chosen to study the antitumor effect of PSI. In an in vivo model of local tumor growth, PSI exerted significant antitumor effects against C-26 colon carcinoma, but not against 3LL lung carcinoma. Retardation of tumor growth was observed in mice treated with both 10 nmoles and 100 nmoles doses of PSI and in the latter group prolongation of the survival time of tumor-bearing mice was observed. PSI inhibited angiogenesis in the C-26 growing tumors with no such effect in 3LL tumors. Unexpectedly, that activity was associated with upregulation of vascular endothelial growth factor (VEGF) at the level of mRNA expression and protein production in C-26 tumors treated with PSI. C-26 cells treated with PSI produced increased amounts of VEGF in vitro in a dose- and time-dependent manner. We demonstrated that in C-26 colon adenocarcionoma higher VEGF production may render endothelial cells susceptible to the proapoptotic activity of PSI and is associated with inhibition of tumor growth.
Collapse
Affiliation(s)
- T Stokłosa
- Department of Immunology, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Jakóbisiak M, Feleszko W, Gołąb J. 107. Potencjalne przeciwnowotworowe działanie statyn. Rep Pract Oncol Radiother 2003. [DOI: 10.1016/s1507-1367(03)70591-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
4
|
Dabrowska A, Giermasz A, Gołab J, Jakóbisiak M. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma 2002; 48:358-61. [PMID: 11845979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-alpha in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.
Collapse
Affiliation(s)
- A Dabrowska
- Department of Immunology, Center of Biostructure, Medical University of Warsaw, Poland
| | | | | | | |
Collapse
|
5
|
Giermasz A, Grzela T, Nowis D, Makowski M, Czajka A, Stoklosa T, Lasek W, Dabrowsk A, Wiznerowicz M, Mackiewicz A, Jakóbisiak M. Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line. Anticancer Res 2001; 21:4001-4. [PMID: 11911283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
Butyric acid (NaBut) and its derivatives are well-known agents eliciting tumor cell differentiation and apoptosis. In experimental models, NaBut is also used to enhance the efficacy of viral vectors. With the use of B78 murine melanoma cells transduced with the retroviral vector containing human tumor necrosis factor alpha (hTNF-alpha) gene, we investigated the ability of NaBut to increase the cytokine expression. We observed an increase in hTNF-alpha expression in vitro after incubation with NaBut. We also describe that the NaBut pro-drug tributyrin is able to increase hTNF-alpha expression in transduced B78 cells in a tumor vaccination model in mice. This observation strongly suggests a novel potential role for NaBut and its derivatives in tumor therapy. It could be used not only as a therapeutic directly acting on tumor cells but, in parallel, as a genetic vaccine "enhancer".
Collapse
Affiliation(s)
- A Giermasz
- Department of Immunology, Centre for Biostructure Research, The Medical University of Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
We examined the effects of lovastatin, a common anti-atherosclerotic drug and a blocker of the cell cycle, on the process of mitosis. It is known that lovastatin induces an arrest or a retardation of the cell cycle in many cell types not only at the G(1)phase, but also at the G(2)/M transition. After 24-48 h incubation of epithelial PtK(2), T24, HeLa cells and fibroblastic L929 cells in the presence of 1. 0-60.0 microm lovastatin, diverse mitotic perturbations have been observed. The most noteworthy phenomena recorded were prometaphase retardation and chromosome lagging during metaphase and anaphase. After the recovery in lovastatin-free media, the cells continued mitosis without any disturbances. Mevalonic acid prevented the effects of lovastatin. We conclude that the effects were specific for lovastatin-induced inhibition of mevalonic acid synthesis. Immunofluorescence studies with anticentromeric antibodies suggested that one of the possible causes of the lovastatin-induced mitotic disorder could be an interference with the development and function of the centromeres.
Collapse
Affiliation(s)
- J Lamprecht
- Department of Histology and Embryology, Medical University of Warsaw, Chalubińskiego 5, Warsaw, 02-004, Poland
| | | | | | | | | | | |
Collapse
|
7
|
Goł b J, Zagozdzon R, Kamiński R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stokłosa T, Giermasz A, Lasek W, Jakóbisiak M. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 2001; 15:613-20. [PMID: 11368364 DOI: 10.1038/sj.leu.2402076] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In this study we investigated the efficacy of a combination of IL-12 and 5-FU, a chemotherapeutic exerting several immunomodulatory effects, in murine L1210 leukemia. Mice inoculated with 1 x 10(5) leukemia cells were treated with a single dose of 5-FU (50 mg/kg) and seven daily doses of IL-12 (100 ng/dose), and were observed for survival. Treatment with IL-12 or 5-FU given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were 70% of long-term (>60 days) survivors among mice treated with both agents simultaneously. Moreover, we observed 100% of long-term survivors when mice were treated with a minimally increased dose of IL-12 (170 ng) in combination with 5-FU (50 mg/kg). The antileukemic effects were completely abrogated in scid/scid mice and in mice depleted of peritoneal macrophages and significantly decreased after administration of anti-CD3+, anti-CD4+ or anti-CD8+ monoclonal antibodies. Administration of anti-NK1.1 antibodies did not decrease the antileukemic effects indicating that NK cells are not important effectors of this treatment regimen. Collectively, these results indicate that the combination of IL-12 and 5-FU is inducing strong antileukemic responses that are dependent on the presence and activity of macrophages and T lymphocytes and warrant further studies of combined chemo-immunotherapy with IL-12.
Collapse
Affiliation(s)
- J Goł b
- Department of Immunology, Center of Biostructsure Research, Medical University of Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M, Czajka A, Młynarczuk I, Hoser G, Stok osa T, Lewandowski S, Jakóbisiak M. Antitumor activity of tributyrin in murine melanoma model. Cancer Lett 2001; 164:143-8. [PMID: 11179828 DOI: 10.1016/s0304-3835(01)00375-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Butyric acid has been known to inhibit growth and to induce differentiation of a variety of tumor cells. Butyrate-treated tumor cells have also been observed to undergo apoptosis. Although butyrate compounds have demonstrated antitumor activity in murine tumor models and have already been admitted to clinical trials in tumor patients, the exact mechanism of their antitumor effects has not been elucidated. The results of our study showed antitumor activity of tributyrin, a butyric acid prodrug, in murine melanoma model and are strongly suggestive that antiangiogenic effects could participate in antitumor effects of butyrate compounds in vivo.
Collapse
Affiliation(s)
- A Giermasz
- Department of Immunology, Centre of Biostructure, The Medical University of Warsaw, ul. Chalubinskiego 5, 02-004, Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Młynarczuk I, Hoser G, Grzela T, Stokłosa T, Wójcik C, Malejczyk J, Jakóbisiak M. Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells. Anticancer Res 2001; 21:1237-40. [PMID: 11396170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
TRAIL, Tumor necrosis factor-related apoptosis-inducing ligand), a member of the TNF family, is known to be cytotoxic for a high proportion of tumor cell lines. However, successful application of TRAIL in tumor therapy may depend on finding other agents that can potentiate its antitumor effects. The present study showed that the cytostatic/cytotoxic TRAIL activity against U937 cells could be significantly augmented by proteasome inhibitor PSI, as revealed by MTT assay. Increased cytostatic/cytotoxic effect on U937 cells by TRAIL/PSI combined treatment was caused by apoptosis, as shown by an increased PARP cleavage rate. TRAIL/PSI did not affect the level of mRNA expression for TRAIL receptors (DR4, DR5, DcR1) and other apoptosis signal transduction molecules (TRADD, caspase-8).
Collapse
Affiliation(s)
- I Młynarczuk
- Department of Immunology, Medical University of Warsaw, 5 Chałubinskiego Str., PL 02 004 Warsaw, Poland
| | | | | | | | | | | | | |
Collapse
|
10
|
Lasek W, Jakóbisiak M. [Cytokines as therapeutics--application in oncology]. Pneumonol Alergol Pol 2001; 67:491-6. [PMID: 11185035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
|
11
|
Lasek W, Mackiewicz A, Czajka A, Switaj T, Goł b J, Wiznerowicz M, Korczak-Kowalska G, Bakowiec-Iskra EZ, Gryska K, Izycki D, Jakóbisiak M. Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther 2000; 7:1581-90. [PMID: 11228537 DOI: 10.1038/sj.cgt.7700263] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In the present study, TNF-alpha gene-transduced B78 melanoma cells (B78/TNF) were used as a vaccine and combined with interleukin (IL)-12 in the treatment of B78 melanoma-bearing mice. The combined administration of genetically modified melanoma cells and IL-12 induced specific protective antitumor immunity resulting in a decreased rate of the tumor take following a rechallenge with parental B78 cells. When used therapeutically, intratumoral injections of irradiated B78/TNF melanoma cells and IL-12 exerted strong antitumor effects and led to complete regression of established tumors in 50% of mice. Injections of irradiated B78/TNF cells alone did not influence tumor development and IL-12 itself significantly delayed tumor growth but without curative effect. FACS analysis of parental B78 melanoma cells and its B78/TNF genetically modified variant showed that a proportion of cells of both cell lines expressed 87-1 (CD80) costimulatory molecule and that the expression of this molecule was increased during incubation with IFN-gamma. Moreover, IFN-gamma markedly augmented expression of major histocompatibility class (MHC) class I and II molecules on B78/TNF cells that were primarily MHC class I and II negative with no substantial effect on MHC-negative parental B78 melanoma. IFN-gamma also synergized in cytostatic/cytotoxic effects with TNF-alpha against B78 melanoma in vitro. Lymphocyte depletion studies in vivo showed reduction of the antitumor response in mice treated with anti - NK monoclonal antibodies (mAbs) as well as in mice treated with anti-CD4+ anti-CD8 mAbs. The results suggest that, when used therapeutically, IL-12 and a vaccine containing TNF-alpha gene-transduced tumor cells may reciprocally augment their overall antitumor effectiveness by facilitating development of systemic antitumor immunity and by stimulating local effector mechanisms of the tumor destruction.
Collapse
Affiliation(s)
- W Lasek
- Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Gołab J, Stokłosa T, Zagozdzon R, Kaca A, Kulchitska LA, Feleszko W, Kawiak J, Hoser G, Głowacka E, Dabrowska A, Giermasz A, Lasek W, Jakóbisiak M. Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumour Biol 2000; 19:77-87. [PMID: 9486559 DOI: 10.1159/000029978] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
To study the antitumor activity of the combination immunotherapy with interleukin-12 (IL-12) and granulocyte-macrophage colony-stimulating factor (GM-CSF), a murine MmB 16 melanoma tumor model was used. Seven days after inoculation of MmB 16 melanoma cells into the footpad of the right hind limb, mice were treated with IL-12 and/or GM-CSF administered intratumorally for 7 consecutive days. IL-12 used both at a high (1 microg) and at a low (0.01 microg) dose per day produced retardation of tumor growth, although neither treatment resulted in any significant prolongation of the survival of tumor-bearing mice. GM-CSF did not by itself exert antitumor activity in this model; however, it potentiated antitumor effects of IL-12. In particular, survival of tumor-bearing mice treated with IL-12 (0.01 microg per day) and GM-CSF was significantly prolonged compared with that in mice treated with either IL-12 or GM-CSF alone.
Collapse
Affiliation(s)
- J Gołab
- Department of Immunology, Institute of Biostructure, Medical School of Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Wójcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I, Pleban E, Basak G, Omura S, Jakóbisiak M. Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol 2000; 32:957-65. [PMID: 11084375 DOI: 10.1016/s1357-2725(00)00044-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Lovastatin and simvastatin are HMG-CoA reductase inhibitors widely used as antihyperlipidemic drugs, which also display antiproliferative properties. In the present paper, we provide evidence that both lovastatin and simvastatin are modulators of the purified bovine pituitary 20 S proteasome, since they mildly stimulate the chymotrypsin-like activity and inhibit the peptidylglutamylpeptide hydrolyzing activity without interfering with the trypsin-like activity. However, those effects are only observed when the closed ring forms of the drugs are used, while the opened ring form of lovastatin acts as a mild inhibitor of the chymotrypsin like activity. The closed ring form of lovastatin is much more potent as a cytotoxic agent on the Colon-26 (C-26) colon carcinoma cell line than the opened ring form, which is only mildly cytostatic. Moreover, neither the cytotoxic effects nor the effects on 20 S proteasome activities are prevented by mevalonate, which by itself inhibits the trypsin-like activity of the proteasome. Neither the opened ring nor the closed ring form of lovastatin induces an accumulation of ubiquitin-protein conjugates, which is observed after treatment with lactacystin, a selective proteasome inhibitor. In contrast with the opened ring form of lovastatin, the closed ring form induces the disappearance of detectable p27(kip1) from C-26 cells. Altogether, our results indicate that the closed ring form of lovastatin induces cytotoxic effects independent of its HMG-CoA inhibiting activity, however, those effects are mediated by a complex modulation of proteasome activity rather than by inhibition of the 20 S proteasome.
Collapse
Affiliation(s)
- C Wójcik
- Department of Histology and Embryology, Biostructure Center, Warsaw Medical Academy, Ul. Chalubinskiego 5, 02-004 Warsaw, Poland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Abstract
A novel pathway of autocrine macrophage activation based on a positive feedback loop involving interleukin (IL)-12, IL-18 and IFN-gamma has recently been suggested. However, the macrophage isolation technique employed to describe the above phenomenon does not allow obtaining a pure population of macrophages casting some doubt to its existence. In the present study, we show that even minor contamination with lymphoid cells of a pure population of macrophage-like cells (Raw 264.7) results in a marked production of nitric oxide after stimulation with both IL-12 and IL-18. Neither macrophage-like cells nor lymphoid cells were capable of secreting high amounts of nitric oxide after stimulation with IL-12 and/or IL-18. Based on these observations we hypothesize that proposed autocrine feedback loop of macrophage activation is rather paracrine in nature and involves direct stimulation of residual lymphoid cells to secrete IFN-gamma that is then capable of activating macrophages.
Collapse
Affiliation(s)
- J Gołab
- Department of Immunology, Institute of Biostructure, The Medical University of Warsaw, ul. Chalubińskiego 5, 02-004, Warsaw, Poland.
| | | | | | | | | |
Collapse
|
15
|
Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jakóbisiak M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000; 6:2044-52. [PMID: 10815931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Lovastatin, a drug commonly used in the clinic to treat hypercholesterolemia, has previously been reported to exert antitumor effects in rodent tumor models and to strengthen the antitumor effects of immune response modifiers (tumor necrosis factor alpha and IFN-gamma) or chemotherapeutic drugs (cisplatin). In the present report, we show in three murine tumor cell lines (Colon-26 cells, v-Ha-ras-transformed NIH-3T3 sarcoma cells, and Lewis lung carcinoma cells) that lovastatin can also effectively potentiate the cytostatic/cytotoxic activity of doxorubicin. In three tumor models (Co-ion-26 cells, v-Ha-ras-transformed NIH-3T3 sarcoma cells, and Lewis lung carcinoma cells) in vivo, we have demonstrated significantly increased sensitivity to the combined treatment with both lovastatin (15 mg/kg for 10 days) and doxorubicin (3 x 2.5 mg/kg; cumulative dose, 7.5 mg/kg) as compared with either agent acting alone. Lovastatin treatment also resulted in a significant reduction of troponin T release by cardiomyocytes in doxorubicin-treated mice. This observation is particularly interesting because lovastatin is known to reduce doxorubicin-induced cardiac injury.
Collapse
MESH Headings
- 3T3 Cells
- Animals
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cell Division/drug effects
- Cell Line, Transformed
- Cell Survival/drug effects
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Doxorubicin/administration & dosage
- Doxorubicin/adverse effects
- Doxorubicin/pharmacology
- Drug Resistance, Neoplasm
- Drug Synergism
- Female
- Heart Diseases/blood
- Heart Diseases/chemically induced
- Heart Diseases/prevention & control
- Lovastatin/administration & dosage
- Lovastatin/pharmacology
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Inbred DBA
- Neoplasm Transplantation
- Neoplasms, Experimental/blood
- Neoplasms, Experimental/drug therapy
- Neoplasms, Experimental/pathology
- Time Factors
- Troponin T/blood
- Troponin T/drug effects
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- W Feleszko
- Department of Immunology, Institute of Biostructure, Warsaw, Poland
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Gołab J, Wilczyński G, Zagozdzon R, Stokłosa T, Dabrowska A, Rybczyńska J, Wasik M, Machaj E, Ołda T, Kozar K, Kamiński R, Giermasz A, Czajka A, Lasek W, Feleszko W, Jakóbisiak M. Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer 2000; 82:1485-91. [PMID: 10780531 PMCID: PMC2363378 DOI: 10.1054/bjoc.1999.1078] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Photofrin-based photodynamic therapy (PDT) has recently been approved for palliative and curative purposes in cancer patients. It has been demonstrated that neutrophils are indispensable for its anti-tumour effectiveness. We decided to evaluate the extent of the anti-tumour effectiveness of PDT combined with administration of granulocyte colony-stimulating factor (G-CSF) as well as the influence of Photofrin and G-CSF on the myelopoiesis and functional activity of neutrophils in mice. An intensive treatment with G-CSF significantly potentiated anti-tumour effectiveness of Photofrin-based PDT resulting in a reduction of tumour growth and prolongation of the survival time of mice bearing two different tumours: colon-26 and Lewis lung carcinoma. Moreover, 33% of C-26-bearing mice were completely cured of their tumours after combined therapy and developed a specific and long-lasting immunity. The tumours treated with both agents contained more infiltrating neutrophils and apoptotic cells then tumours treated with either G-CSF or PDT only. Importantly, simultaneous administration of Photofrin and G-CSF stimulated bone marrow and spleen myelopoiesis that resulted in an increased number of neutrophils demonstrating functional characteristics of activation. Potentiated anti-tumour effects of Photofrin-based PDT combined with G-CSF observed in two murine tumour models suggest that clinical trials using this tumour therapy protocol would be worth pursuing.
Collapse
Affiliation(s)
- J Gołab
- Department of Immunology, Institute of Biostructure, Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Feleszko W, Jakóbisiak M. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 2000; 6:1198-9. [PMID: 10741752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
|
18
|
Gołab J, Kozar K, Kamiński R, Czajka A, Marczak M, Switaj T, Giermasz A, Stokłosa T, Lasek W, Zagozdzon R, Mucha K, Jakóbisiak M. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci 2000; 66:1223-30. [PMID: 10737417 DOI: 10.1016/s0024-3205(00)00427-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Nonsteroidal anti-inflammatory drugs have been shown to reduce the incidence and mortality from colorectal cancer. It has recently been demonstrated that these drugs are capable of suppressing the production of pro-angiogenic factors from tumor cells. The mechanisms of antitumor action of interleukin 12 include the enforced secretion of anti-angiogenic factors and stimulation of antitumor immunity. Therefore, we hypothesized that the combination of a model nonsteroidal anti-inflammatory drug--indomethacin and interleukin 12--would result in enhanced angiogenesis-dependent antitumor effects against a colon-26 carcinoma cells transplanted into syngeneic mice. As expected the combined administration of both agents simultaneously resulted in a strengthened antitumor activity that was manifested as a retardation of tumor growth and prolongation of mouse survival. Importantly some mice were completely cured after the combined treatment. As administration of interleukin 12 and indomethacin resulted in enhanced inhibition of angiogenesis it seems possible that prevention of new blood vessel formation is one of the mechanisms responsible for the observed antitumor effects.
Collapse
Affiliation(s)
- J Gołab
- Department of Immunology, Institute of Biostructure, The Medical University of Warsaw, Poland.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Dabrowska A, Giermasz A, Marczak M, Gołab J, Jakóbisiak M. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. Anticancer Res 2000; 20:391-4. [PMID: 10769685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-gamma production stimulated by IL-12. Since IFN-gamma has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors--batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.
Collapse
MESH Headings
- Adjuvants, Immunologic/pharmacology
- Adjuvants, Immunologic/therapeutic use
- Angiogenesis Inhibitors/pharmacology
- Angiogenesis Inhibitors/therapeutic use
- Animals
- Drug Synergism
- Interleukin-12/pharmacology
- Interleukin-12/therapeutic use
- Melanoma, Experimental/blood supply
- Melanoma, Experimental/drug therapy
- Melanoma, Experimental/enzymology
- Melanoma, Experimental/pathology
- Metalloendopeptidases/antagonists & inhibitors
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Inbred DBA
- Neoplasm Proteins/antagonists & inhibitors
- Neoplasm Transplantation
- Neovascularization, Pathologic/drug therapy
- Phenylalanine/analogs & derivatives
- Phenylalanine/pharmacology
- Phenylalanine/therapeutic use
- Protease Inhibitors/pharmacology
- Protease Inhibitors/therapeutic use
- Recombinant Proteins/pharmacology
- Recombinant Proteins/therapeutic use
- Thiophenes/pharmacology
- Thiophenes/therapeutic use
- Tumor Cells, Cultured/transplantation
Collapse
Affiliation(s)
- A Dabrowska
- Department of Immunology, Medical University of Warsaw, Poland
| | | | | | | | | |
Collapse
|
20
|
Zagozdzon R, Giermasz A, Gołab J, Stokłosa T, Jalili A, Jakóbisiak M. The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. Cancer Lett 1999; 147:67-75. [PMID: 10660091 DOI: 10.1016/s0304-3835(99)00277-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In our recent study we described a significant antileukemic efficacy of a combination therapy with interleukin-12 (IL-12) and doxorubicin (DOX) in the L1210 leukemia model. This therapeutic effect was abrogated by elimination of activated macrophages. Activated macrophages produce a variety of factors that can contribute to the elimination of tumor cells in vivo, including proteases, TNF, reactive oxygen intermediates, and nitric oxide (NO). Based on the results of previous reports, the contribution of NO in potentiated antileukemic effects of IL-12 + DOX combination seemed to be highly possible. Both DOX and IL-12 given alone increased the production of NO by peritoneal macrophages, however, macrophages derived from the mice treated with the combination of those agents produced significantly less NO than macrophages from IL-12-alone-treated mice. Production of NO by spleen macrophages after IL-12 + DOX treatment was higher than it was in controls, IL-12-alone or DOX-alone-treated groups. In serum, concentrations of NOx- in IL-12- or IL-12 + DOX-treated mice were significantly higher in comparison with controls, however not significantly different from each other. Addition of L-NAME treatment to the IL-12 + DOX therapy in leukemia-bearing mice did not significantly change the antileukemic efficacy of this therapy. Thus, our results indicate that the augmented antileukemic effects of IL-12 + DOX combination therapy in L1210 model are NO-independent. Therefore, further studies on the possible mechanisms of potentiated antileukemic activity of combination of IL-12 and DOX would be worth pursuing.
Collapse
Affiliation(s)
- R Zagozdzon
- Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland.
| | | | | | | | | | | |
Collapse
|
21
|
Lasek W, Golab J, Maśliński W, Switaj T, Bałkowiec EZ, Stokłosa T, Giermasz A, Malejczyk M, Jakóbisiak M. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Eur Cytokine Netw 1999; 10:345-56. [PMID: 10477391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Interleukin-12 (IL-12) is a potent immunoregulatory cytokine that exhibits antitumor activity in many experimental tumor models. In the present study, we investigated the ability of IL-15, a cytokine sharing many functions of IL-2, to modulate antitumor effectiveness of IL-12 against B16F10 melanoma in mice. In a model of locally growing tumor, intratumoral (i.t.) administration of IL-12, in three cycles of five consecutive daily injections (0.1 mug) followed by 2 days of rest, led to considerable delay of tumor development but no curative response was achieved. When combined with IL-12, subtherapeutic doses of IL-15 (0.4 mug) pontentiated the antitumor effects of IL-12 and induced complete tumor regressions in 50% of mice. Similar results were obtained in a model in which tumor-bearing mice were intravenously co-injected with melanoma cells to induce metastases. Combined administration of IL-12 and IL-15 yielded greater antitumor activity than injections of either cytokine alone and resulted in prolonged survival of mice bearing locally growing tumor and metastases. Studies of immunological parameters in mice treated with both IL-12 and IL-15 have shown enhanced NK activity (against YAC-1 cells) in the spleen and stimulation of both NK activity and specific anti-B16F10 cytotoxic effector cells in tumor-draining lymph nodes (LN). The strong antitumor effect of the IL-12 + IL-15 combination correlated with a high serum level of IFN-gamma in the treated mice. Moreover, increased expression of IL-15Ralpha was demonstrated in LN lymphocytes isolated from mice injected with IL-12. This result together with findings of other authors showing enhanced expression of IL-12 receptor by IL-15 [1] suggests that the augmentation of the antitumor effect during the course of IL-12/IL-15-based therapy could result from reciprocal upregulation of receptors by both cytokines and synergistic effects on IFN-gamma induction.
Collapse
Affiliation(s)
- W Lasek
- Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Feleszko W, Bałkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A, Jakóbisiak M. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 1999; 81:560-7. [PMID: 10225445 DOI: 10.1002/(sici)1097-0215(19990517)81:4<560::aid-ijc10>3.0.co;2-7] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Lovastatin, a drug commonly used in the treatment of hypercholesterolemia, has previously been reported to exert potentiated antitumor activity when combined with either tumor necrosis factor-alpha (TNF-alpha), cisplatin or doxorubicin in a melanoma model in mice. Since lovastatin interferes with the function of ras oncogene-encoded (Ras) proteins, we have investigated the antitumor activity of lovastatin and TNF-alpha using a Ha-ras-transformed murine tumor model. In in vitro studies, lovastatin inhibited the growth of cells transformed with Ha-ras oncogene (Ras-3T3 and HBL100-ras cells) more effectively than control NIH-3T3 and HBL100-neo cells. In in vivo experiments, the Ras-3T3 tumor demonstrated significantly increased sensitivity to combined treatment with both lovastatin (50 mg/kg) and TNF-alpha (1 microg/day) compared with either agent alone. Combined treatment with both agents also resulted in greater inhibition of blood-vessel formation. Ras-3T3 tumor cells produced increased amounts of vascular endothelial growth factor (VEGF) and lovastatin effectively suppressed VEGF production by these cells. Our results suggest that lovastatin increases antitumor activity of TNF-alpha against tumor cells transformed with v-Ha-ras oncogene via inhibition of tumor-induced blood-vessel formation.
Collapse
Affiliation(s)
- W Feleszko
- Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Medical University Children's Hospital, Poland
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Dabrowska A, Golab J, Giermasz A, Marczak M, Jakóbisiak M. Re: Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 1999; 91:804-6. [PMID: 10328115 DOI: 10.1093/jnci/91.9.804b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Zagozdzon R, Gołab J, Stokłosa T, Giermasz A, Nowicka D, Feleszko W, Lasek W, Jakóbisiak M. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 1998; 77:720-7. [PMID: 9688305 DOI: 10.1002/(sici)1097-0215(19980831)77:5<720::aid-ijc10>3.0.co;2-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
It has been well established that chemo-immunotherapy using cytotoxic drugs and appropriate cytokines offers a new approach to increasing the therapeutic index in the treatment of neoplastic diseases. This study investigates the efficacy of combinations of interleukin-12 with cyclophosphamide, paclitaxel, cisplatin or doxorubicin in the murine L1210 leukemia model. Mice inoculated i.p. with 1 x 10(3) or 1 x 10(5) leukemia cells were treated with interleukin-12 and/or chemotherapeutics, and were observed daily for survival. Immunosuppression with X-irradiation or macrophage depletion with injections of silica were used to examine the dependence of the therapeutic effects on the efficiency of the immune system. Treatment with interleukin-12 or one of the studied chemotherapeutics given alone resulted in moderate antileukemic effects. Combination of interleukin-12 with cyclophosphamide or paclitaxel produced no augmentation of anti-leukemic effects in comparison with these agents given alone. Combination of interleukin-12 with cisplatin resulted in prolongation of the survival time; however, in the experiment with mice inoculated with 1 x 10(5) leukemia cells, no long-term survivors (>60 days) were observed; on the contrary, combination of interleukin-12 with doxorubicin resulted in 100% long-term survivors. This effect was completely abrogated either by X-irradiation of mice or by macrophage depletion. We also found that doxorubicin augments IL-12-stimulated production of interferon-gamma in vivo. Our observations demonstrating potentiation of the antileukemic effects of the IL-12 and doxorubicin combination suggest that the combined use of these 2 agents could be beneficial in leukemia therapy.
Collapse
Affiliation(s)
- R Zagozdzon
- Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Gołab J, Zagozdzon R, Stokłosa T, Jakóbisiak M, Pojda Z, Machaj E. Erythropoietin prevents the development of interleukin-12-induced anemia and thrombocytopenia but does not decrease its antitumor activity in mice. Blood 1998; 91:4387-8. [PMID: 9596689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
26
|
Gołab J, Zagozdzon R, Stokłosa T, Kaca A, Dabrowska A, Giermasz A, Feleszko W, Jakóbisiak M. Granulocyte colony-stimulating factor demonstrates antitumor activity in melanoma model in mice. Neoplasma 1998; 45:35-9. [PMID: 9605000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Granulocyte colony-stimulating factor (G-CSF) was found to exert antitumor activity against murine MmB16 melanoma when administered intratumorally. However, subcutaneous administration of this cytokine at a site distant from the growing tumor did not show any antitumor effects. G-CSF did not influence the proliferative activity of MmB16 in vitro. Intraperitoneal administration of G-CSF resulted in decreased secretion of nitric oxide (NO) by peritoneal macrophages and their decreased tumoricidal activity against MmB16.
Collapse
Affiliation(s)
- J Gołab
- Department of Immunology, Institute of Biostructure, Medical School of Warsaw, Poland
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Lovastatin, the drug used in the treatment of hypercholesterolaemia, has previously been reported to exert synergistic antitumour activity in a melanoma model in mice when used together with some immune response modifiers. In this study, we examined the antitumour effect of cisplatin augmented by its combined application with lovastatin, both in vitro and in vivo, in a murine melanoma model. The results of this study suggest that lovastatin may enhance the therapeutic effects of cisplatin in the treatment of malignant melanomas.
Collapse
Affiliation(s)
- W Feleszko
- Department of Immunology, Institute of Biostructure, Medical School, Warsaw, Poland
| | | | | | | |
Collapse
|
28
|
Gołab J, Stokłosa T, Zagozdzon R, Kaca A, Giermasz A, Pojda Z, Machaj E, Dabrowska A, Feleszko W, Lasek W, Iwan-Osiecka A, Jakóbisiak M. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 1998; 9:63-9. [PMID: 9541685 DOI: 10.1023/a:1008266321552] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND IL-12 has been successfully used in experimental tumor therapy. However, administration of this cytokine induces dose-dependent suppression of hematopoiesis that could potentially limit its use in clinical trials. We decided to examine whether the myelosuppressive activity of IL-12 could be corrected by the administration of G-CSF. MATERIALS AND METHODS In the initial experiments the influence of IL-12 and/or G-CSF on bone marrow and spleen GM-CFC was evaluated. To examine whether C-CSF could influence the antitumor activity of IL-12 the combination therapy with these agents was carried out starting on day seven following inoculation of melanoma MmB16 cells into the footpads of B6D2F1 mice. To obtain insight into the mechanism of the observed augmented antitumor activity of the combination therapy with IL-12 and G-CSF, the influence of these cytokines on macrophage activity (cytotoxicity and nitric oxide release) was analyzed. RESULTS In accord with our expectations, the application of G-CSF partially prevented the suppression of bone marrow myelopoiesis in IL-12 treated mice. Unexpectedly, G-CSF also showed potentiation of antitumor effects of IL-12 in this melanoma model. The augmented antitumor activity of combined IL-12/G-CSF immunotherapy could result from the enhanced stimulation of macrophage NO production and cytotoxicity. CONCLUSION The simultaneous administration of IL-12 and G-CSF partially prevented suppression of bone marrow myelopoiesis in IL-12-treated mice. Moreover, treatment with these cytokines also results in potentiated antitumor effects in a murine melanoma model.
Collapse
Affiliation(s)
- J Gołab
- Department of Immunology, Medical School of Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Zagozdzon R, Stokłosa T, Gołab J, Giermasz A, Dabrowska A, Lasek W, Jakóbisiak M. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Res 1997; 17:4493-8. [PMID: 9494557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Interleukin-12 (IL-12) has demonstrated antitumor activity in many murine tumor models. However, toxic effects resulting from treatment with IL-12 have been also described. Combining IL-12 with other antineoplastic agents could potentiate its antitumor efficacy and, furthermore, could minimize its toxicity by reducing the doses necessary to achieve the antitumor activity. We examined in a murine melanoma model the efficacy of combination tumor chemo-immunotherapy based on administration of IL-12, cisplatin (CDDP), and tumor necrosis factor-alpha (TNF-alpha). In the current study pairs of: IL-12 + CDDP and IL-12 + TNF-alpha, showed stronger antitumor activity than either agent given alone. Furthermore, combination tumor therapy with IL-12 + CDDP + TNF-alpha was more effective at retarding local tumor growth than either IL-12 + CDDP, IL-12 + TNF-alpha or CDDP + TNF-alpha combination therapies. Our observations indicate that combining of CDDP with IL-12 and IL-12 with TNF-alpha as well as using the triple combination of CDDP, IL-12 and TNF-alpha could be beneficial in tumor therapy.
Collapse
Affiliation(s)
- R Zagozdzon
- Department of Immunology, Medical School of Warsaw, Poland
| | | | | | | | | | | | | |
Collapse
|
30
|
Lasek W, Feleszko W, Golab J, Stokłosa T, Marczak M, Dabrowska A, Malejczyk M, Jakóbisiak M. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 1997; 45:100-8. [PMID: 9390201 PMCID: PMC11037568 DOI: 10.1007/s002620050408] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
There is strong evidence that antitumor activity of interleukin-12 (IL-12) in vivo is mediated, in part, through interferon (IFN gamma) produced by IL-12-stimulated natural killer and T cells. Since IFN gamma and tumor necrosis factor alpha (TNF alpha) have been reported to synergize in antitumor effects in a number of models, we decided to examine whether the combined treatment with recombinant mouse IL-12 and recombinant human TNF alpha would produce similar effects. The efficacy of the combined IL-12/TNF alpha immunotherapy was evaluated in three tumor models in mice: B16F10 melanoma, Lewis lung (LL/2) carcinoma and L1 sarcoma. Intratumoral daily injections of 1 microgram IL-12 in combination with 5 micrograms TNF alpha into B16F10-melanoma-bearing mice resulted in a significant retardation of the tumor growth as compared with that in controls and in mice treated with either cytokine alone. Similar effects were obtained using 0.1 microgram IL-12 and 5 micrograms TNF alpha in LL/2 carcinoma and L1 sarcoma models. Antitumor activity against L1 sarcoma was still preserved when TNF alpha at a low dose (1 microgram) was combined with 0.1 microgram IL-12 and applied for a prolonged time. Potentiation of antitumor effects, which was observed in IL-12/TNF alpha-based immunotherapy, could result from at least three different mechanisms, partly related to stimulation of IFN gamma and TNF alpha production in treated mice: (a) direct cytostatic/cytotoxic effects on tumor cells, (b) induction of antitumor activity of macrophages, and (c) inhibition of blood vessel formation in the tumor. Our studies demonstrate that combination tumor immunotherapy with IL-12 and TNF alpha may be more effective than single-cytokine treatment, and suggest possible mechanisms by which IL-12 and TNF alpha may exert potentiated therapeutic effects against locally growing tumors.
Collapse
Affiliation(s)
- W Lasek
- Department of Immunology, Medical School of Warsaw, Poland
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Wójcik C, Stoklosa T, Giermasz A, Golab J, Zagozdzon R, Kawiak J, Wilk S, Komar A, Kaca A, Malejczyk J, Jakóbisiak M. Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis 1997; 2:455-62. [PMID: 14646528 DOI: 10.1023/a:1026470027387] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Of a number of factors involved in apoptosis, protease activity may play a crucial role. We show that N-benzyloxycarbonyl-Ile-Glu( O-t-butyl)-Ala-leucinal (PSI), a selective inhibitor of the chymotrypsin-like activity of the proteasome, induces massive apoptosis in murine leukaemia L1210 cells. At 50 nM concentration, PSI induces a block of cytokinesis, while higher concentrations (500 nM) cause S phase block and massive apoptosis. Z-Leu-leucinal, a specific calpain inhibitor, did not induce apoptosis. In contrast to previous reports, TNF-alpha did not enhance apoptosis when combined with PSI. Our results suggest that proteasome inhibitors may be considered as potential anti-neoplastic agents.
Collapse
Affiliation(s)
- C Wójcik
- Laboratory for Molecular Cell Biology, Department of Histology and Embryology, Institute of Biostructure, Warsaw Medical School, Poland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lasek W, Giermasz A, Kuc K, Wańkowicz A, Feleszko W, Gołab J, Zagozdzon R, Stokłosa T, Jakóbisiak M. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer 1996; 66:374-9. [PMID: 8621260 DOI: 10.1002/(sici)1097-0215(19960503)66:3<374::aid-ijc18>3.0.co;2-b] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The anti-tumor effects of actinomycin D (Act D) and recombinant human tumor necrosis factor (TNF)-alpha have been studied on 4 established murine tumor cell lines: MmB16 melanoma, Lewis lung (LL/2) carcinoma, L1 sarcoma and L1210 leukemia. During short-term incubation (24 hr) Act D produced dose-dependent cytostatic/cytotoxic effects against MmB16, LL/2 and L1 tumor cells but did not reduce the viability of these cells even at high concentration (10 micrograms/ml), below a threshold of 30-60%. However, L1210 leukemic cells were highly susceptible to Act D, and no viable cells were detected in cultures incubated with 1 microgram/ml of Act D. TNF-alpha alone, when used under the same culture conditions, had only a negligible effect on all cell lines tested. However, the combination of this cytokine with Act D produced synergistic cytotoxic effects against MmB16, LL/2 and L1 cells but not against L1210 leukemia cells. In an in vivo model of regional therapy in which tumor-bearing mice were treated with Act D and TNF-alpha, a correlation with in vitro results was observed. In mice bearing MmB16 melanoma, LL/2 carcinoma and L1 sarcoma, the most potent anti-tumor effects were observed in mice treated with Act D and TNF-alpha together. This treatment led to a delay of tumor growth and induced complete tumor regression in some cases. On the contrary, TNF-alpha did not enhance the effect of Act D in mice injected with L1210 leukemia cells. Our results show that TNF-alpha can potentiate the anti-tumor effects of Act D against tumors weakly susceptible to Act D and may be a useful adjuvant to chemotherapy in the local treatment of neoplasia.
Collapse
MESH Headings
- Animals
- Antibiotics, Antineoplastic/therapeutic use
- Antibiotics, Antineoplastic/toxicity
- Cell Line
- Dactinomycin/therapeutic use
- Dactinomycin/toxicity
- Drug Synergism
- Leukemia L1210/drug therapy
- Lung Neoplasms/drug therapy
- Melanoma, Experimental/drug therapy
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Inbred DBA
- Neoplasms, Experimental/drug therapy
- Neoplasms, Experimental/pathology
- Sarcoma, Experimental/drug therapy
- Time Factors
- Tumor Cells, Cultured
- Tumor Necrosis Factor-alpha/therapeutic use
- Tumor Necrosis Factor-alpha/toxicity
Collapse
Affiliation(s)
- W Lasek
- Department of Immunology, Institute of Biostructure Medical School, Warsaw, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Feleszko W, Giermasz A, Gołatb J, Lasek W, Kuc K, Szperl M, Jakóbisiak M. Granulocyte-macrophage colony-stimulating factor accelerates growth of Lewis lung carcinoma in mice. Cancer Lett 1996; 101:193-7. [PMID: 8620469 DOI: 10.1016/0304-3835(96)04134-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has not been found to exert any influence on the proliferation of Lewis lung carcinoma (LLC) cells in vitro. Nevertheless, when administered intraperitoneally, GM-CSF accelerated the growth of subcutaneously growing LLC in mice.
Collapse
Affiliation(s)
- W Feleszko
- Department of Immunology, Medical School, Warsaw, Poland
| | | | | | | | | | | | | |
Collapse
|
34
|
Lasek W, Wańkowicz A, Kuc K, Feleszko W, Giermasz A, Jakóbisiak M. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice. Oncology 1996; 53:31-7. [PMID: 8570128 DOI: 10.1159/000227531] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The efficacy of combination treatment with actinomycin D (Act D), recombinant human tumor necrosis factor-alpha (TNF-alpha), and recombinant murine interferon-gamma (IFN-gamma) was examined on established MmB16 melanoma in mice. TNF-alpha alone had marginal effect in vitro on melanoma cells. However, when this cytokine was combined with either Act D or IFN-gamma, synergistic cytostatic/cytotoxic effects were observed. The highest cytotoxicity was demonstrated in cultures of melanoma cells in which all three agents together were added. In mice inoculated with 10(6) melanoma cells (into the footpad of the hind limb) and treated locally with Act D, TNF-alpha and IFN-gamma, beneficial therapeutic effects were found. When initiated 1 week after tumor cell inoculation, the 7-day treatment with all these agents administered together at daily doses: 0.2 microgram (Act D), 1 microgram (TNF-alpha), and 200 U (IFN-gamma) resulted in a significant delay of tumor progression in comparison to the therapy that included either Act D alone or TNF-alpha in combination with IFN-gamma. Side effects of such a treatment, both local and systemic, were negligible. The results of this study demonstrate that combination of regional chemotherapy (actinomycin D) and immunotherapy (TNF-alpha/IFN-gamma) may display higher efficacy than either treatment alone and may increase therapeutic index without augmenting toxic effects.
Collapse
Affiliation(s)
- W Lasek
- Department of Immunology, Institute of Biostructure, Medical School of Warsaw, Poland
| | | | | | | | | | | |
Collapse
|
35
|
Lasek W, Wańkowicz A, Kuc K, Feleszko W, Gołab J, Giermasz A, Wiktor-Jedrzejczak W, Jakóbisiak M. Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunol Immunother 1995; 40:315-21. [PMID: 7600564 PMCID: PMC11037724 DOI: 10.1007/bf01519632] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/1994] [Accepted: 01/23/1995] [Indexed: 01/26/2023]
Abstract
The efficacy of systemic infusion of recombinant human macrophage-colony-stimulating factor (M-CSF) in combination with local treatment with human recombinant tumor necrosis factor (TNF) alpha and mouse recombinant interferon (IFN) gamma was studied in vivo on a subclone of B16 melanoma (MmB16) in mice. Short-term intravenous administration of M-CSF at a dose of 10(6) units daily had no antitumor effect in vivo. Similarly, local treatment of tumor with TNF alpha (5 micrograms daily) did not produce any therapeutic effect. However, simultaneous administration of the same dose of TNF alpha with IFN gamma (1000 units daily) resulted in a synergistic effects manifested by the retardation of tumor growth. Addition of systemic infusion of M-CSF to the local therapy with TNF alpha and IFN gamma induced further augmentation of antitumor efficacy and delayed progression of MmB16 melanoma. The strengthened antitumor effect of combination therapy including M-CSF, TNF alpha and IFN gamma was most probably due to the increased release of monocytes from the bone marrow, their recruitment into the site of tumor growth and subsequent local stimulation of their antitumor activity.
Collapse
Affiliation(s)
- W Lasek
- Department of Immunology, Medical School of Warsaw, Poland
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Lasek W, Sora M, Wańkowicz A, Jakóbisiak M. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice. Cancer Lett 1995; 89:137-43. [PMID: 7882296 DOI: 10.1016/0304-3835(95)90169-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The therapeutic effects of the combination of chemotherapy (cyclophosphamide and actinomycin D) and immunotherapy (TNF-alpha and macrophages) were evaluated on L1210 leukemia in mice. When given as single agents, both cyclophosphamide (CY), administered intraperitoneally 2 days after subcutaneous inoculation of leukemic cells, and actinomycin D (Act D), injected intratumorally (i.t.) 4 days following injection of leukemic cells, exerted therapeutic effects and prolonged mice survival. Unexpectedly, combination of CY and Act D did not result in prolongation of mice survival, due mainly to substantial cumulative toxic effects that led to death in several cases. Immunotherapy with TNF-alpha and M phi, injected i.t. on day 4 following inoculation of leukemic cells, did not give significant therapeutic effect, either when used alone or when used in conjunction. However, combination of chemotherapy and immunotherapy, including all four agents, produced a beneficial effect resulting in significant prolongation of the survival of leukemia-bearing mice. This study indicates the potential of appropriate combinations of cytotoxic drugs with immunotherapy against neoplasia.
Collapse
Affiliation(s)
- W Lasek
- Department of Immunology, Medical School of Warsaw, Poland
| | | | | | | |
Collapse
|
37
|
Górecki DC, Jakóbisiak M, Kruszewski A, Lasek W. Evidence that liposome incorporation of cyclosporine reduces its toxicity and potentiates its ability to prolong survival of cardiac allografts in mice. Transplantation 1991; 52:766-9. [PMID: 1949160 DOI: 10.1097/00007890-199111000-00002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Using liposomes, multilamellar lipid vesicles (MLV), we have found that liposome-incorporated cyclosporine is not only less toxic but also more effective in prolonging survival of cardiac allografts in mice. Following intravenous injection of liposome-incorporated drug, cyclosporine levels in blood were shown to decrease rapidly, while concentrations in spleen were higher (when compared with concentration following administration of commercial preparation). In this context, possible mechanisms of the beneficial effect of liposome-incorporated cyclosporine are discussed.
Collapse
Affiliation(s)
- D C Górecki
- Department of Histology and Embryology, Institute of Biostructure, Medical School, Warsaw, Poland
| | | | | | | |
Collapse
|
38
|
Abstract
Lovastatin (LOV), the drug recently introduced to treat hypercholesteremia, inhibits the synthesis of mevalonic acid. The effects of LOV on the cell cycle progression of the human bladder carcinoma T24 cell line expressing activated p21ras were investigated. At a concentration of 2-10 microM, LOV arrested cells in G1 and also prolonged--or arrested a minor fraction of cells in--the G2 phase of the cell cycle; at a concentration of 50 microM, LOV was cytotoxic. The cytostatic effects were reversed by addition of exogenous mevalonate. Cells arrested in the cycle by LOV were viable for up to 72 hr and did not show any changes in RNA or protein content or chromatin condensation, which would be typical of either unbalanced growth or deep quiescence. The expression of the proliferation-associated nuclear proteins Ki-67 and p105 in these cells was reduced by up to 72% and 74%, respectively, compared with exponentially growing control cells. After removal of LOV, the cells resumed progression through the cycle; they entered S phase asynchronously after a lag of approximately 6 hr. Because mevalonate is essential for the posttranslational modification (isoprenylation) of p21ras, which in turn allows this protein to become attached to the cell membrane, the data suggest that the LOV-induced G1 arrest may be a consequence of the loss of the signal transduction capacity of p21ras. Indeed, while exposure of cells to LOV had no effect on the cellular content of p21ras (detected immunocytochemically), it altered the intracellular location of this protein, causing its dissociation from the cell membrane and translocation toward the cytoplasm and nucleus. However, it is also possible that inhibition of isoprenylation of proteins other than p21ras (e.g., nuclear lamins) by LOV may be responsible for the observed suppression of growth of T24 cells.
Collapse
Affiliation(s)
- M Jakóbisiak
- Sloan-Kettering Institute for Cancer Research, New York, NY 10021
| | | | | | | |
Collapse
|
39
|
Górecki D, Kruszewski A, Jakóbisiak M, Lasek W. Local administration of cyclosporin allows reduction of the dose prolonging survival of heart tissue allografts. Immunol Lett 1990; 23:247-9. [PMID: 2347600 DOI: 10.1016/0165-2478(90)90067-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In the H-2-incompatible donor-recipient combination (BALB/c----CBA/H) local administration of cyclosporin allows a 4-fold reduction in a single dose prolonging survival of heart tissue allografts. These results suggest that local administration of cyclosporin may be useful for certain grafts.
Collapse
Affiliation(s)
- D Górecki
- Department of Histology and Embryology, Medical School, Warsaw, Poland
| | | | | | | |
Collapse
|
40
|
Górecki D, Jakóbisiak M, Lupińska M, Kruszewski A, Czyźyk J. Donor-specific transfusion via the portal venous route induces prolongation of H-2-compatible but not H-2-incompatible cardiac graft survival. Transpl Int 1989; 2:199-202. [PMID: 2627262 DOI: 10.1007/bf02414534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
In the H-2-compatible donor-recipient combination (BALB/c----DBA/2), pretransplant donor-specific blood transfusion (DST) via the portal venous (PV) route significantly prolonged cardiac graft survival. DST via the intravenous (IV) route (systemic circulation) also showed a marked prolongation of heart tissue transplant survival in this model. In the H-2-incompatible combination (BALB/c----CBA/H), DST via the IV - but not via the PV - route resulted in accelerated graft rejection.
Collapse
Affiliation(s)
- D Górecki
- Department of Histology and Embryology, Institute of Biostructure, Medical School, Warsaw, Poland
| | | | | | | | | |
Collapse
|
41
|
Lasek W, Jakóbisiak M, Grochowska M, Górecki D, Gniadecki R, Kaliński P. The influence of pretransplant and posttransplant immunosuppression on cardiac graft survival in the donor-specific transfusion model in mice. Comparison of the effects of cyclophosphamide, procarbazine, cyclosporine, and cortisone. Transplantation 1989; 47:913-5. [PMID: 2655232 DOI: 10.1097/00007890-198905000-00038] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- W Lasek
- Department of Transplantology, Institute of Biostructure, Medical School, Warsaw, Poland
| | | | | | | | | | | |
Collapse
|
42
|
Górecki D, Jakóbisiak M, Lupińska M, Kruszewski A, Czyńyk J. Donor-specific transfusion via the portal venous route induces prolongation of H-2-compatible but not H-2-incompatible cardiac graft survival. Transpl Int 1989. [DOI: 10.1111/j.1432-2277.1989.tb01866.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Lasek W, Jakóbisiak M, Płodzisewska M, Szczytnicki W, Górecki D. The role of drug timing and histoincompatibility barrier in prolongation of cardiac graft survival in mice treated with donor-specific blood and cyclophosphamide. Immunol Lett 1988; 17:357-60. [PMID: 3286491 DOI: 10.1016/0165-2478(88)90011-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
In the H-2-compatible donor-recipient combination (BALB/c----DBA/2), pretransplant donor-specific blood transfusion (DST) significantly prolonged graft survival. Concomitant use of immunosuppression by cyclophosphamide (CY) brought about potentiation of DST effect, resulting in long-term graft survival. In contrast, in the 'strong' H-2-incompatible combination (BALB/c----CBA/H) pretreatment of the recipients with donor-specific blood resulted in hyperacute graft rejection or in impairment of drug-induced immunosuppression when DST was used with a single dose of CY. In this model however, combination of DST with both pre- and posttransplant CY immunosuppression interacted beneficially to produce significant donor-specific prolongation of graft survival.
Collapse
Affiliation(s)
- W Lasek
- Department of Transplantology, Institute of Biostructure, Medical School, Warsaw, Poland
| | | | | | | | | |
Collapse
|
44
|
Włodarski K, Mazur S, Jakóbisiak M. Decrease of mast cells in regional lymph nodes in response to allogeneic antigens and syngeneic tumor antigens. Experientia 1982; 38:1105-6. [PMID: 6182025 DOI: 10.1007/bf01955392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
45
|
Jakóbisiak M, Janowska-Wieczorek A, Dobaczewska H, Kańtoch M, Marczak M, Oblakowski P, Lasek W, Sosnowska M. Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man. Scand J Haematol 1981; 27:181-5. [PMID: 6947403 DOI: 10.1111/j.1600-0609.1981.tb00470.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Antibody-dependent cellular cytotoxicity (ADCC) by cells from peripheral blood was studied in patients with; chronic lymphocytic leukaemia (CLL), chronic granulocytic leukaemia (CGL), acute lymphoblastic leukaemia (ALL), acute non-lymphoid leukaemia (ANLL) and compared with that of healthy donors. The ADCC activity in all the types of leukaemia was on the average lower as compared with the control values, being especially low in both CLL and CGL. Further, it has also been shown that the ADCC activity of non-leukaemic blood cells in ANLL was lower as compared with control values. The latter observation indicates that, at least in ANLL, the reduced ADCC potential of peripheral blood cells is not due to dilution of effector cells by poorly- or non-active leukaemic cells.
Collapse
|
46
|
Jakóbisiak M, Kańtoch M, Lasek W, Rozmysłowicz T, Obłakowski P, Dobaczewska H. Augmentation of in vivo antitumour activity of xenogeneic antiserum by autotransplanted normal spleen cells in mice. Eur J Cancer 1981; 17:77-80. [PMID: 7262149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
47
|
Kamiński MJ, Jakóbisiak M. Presence of natural killer cells in Peyer's patches of the mouse. Experientia 1980; 36:1418. [PMID: 6162670 DOI: 10.1007/bf01960135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Natural cell-mediated cytotoxicity of normal murine Peyer's patch cells against Ehrlich ascites carcinoma was found in a short-term 51Cr release assay. Peyer's patch and lymph node cells showed natural cytotoxicity at approximately the same level.
Collapse
|
48
|
Włodarski K, Jakóbisiak M, Janowska-Wieczorek A. Heterotopically induced bone marrow formation: morphology and transplantation. Exp Hematol 1980; 8:1016-23. [PMID: 7009188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Following heterotopic osteogenesis by implantation of xenogeneic epithelia, established human amnion cell lines FL and WISH, and isolated transitional epithelium of dogs in mice, biogenesis of hematopoietic tissue among the induced bone ossicles was observed. Precursors and mature forms of erythroid, granuloid, lymphoid and megakaryocytic series were found in the induced bone marrow. The concentration of lymphocytes in the induced marrow was higher and that of erythropoietic cells lower as compared with orthotopic femur bone marrow. The yield of myeloid cells varied from 0.31 to 14.5 X 10(6) per induced bone nodule, and was higher when uroepithelium was used as an inductor. The induced bone marrow contained hemopoietic stem cells in concentration similar to that of medullar bone marrow and the induced bone marrow protected lethally irradiated syngeneic recipients when used in the same doses as orthotopic bone marrow.
Collapse
|
49
|
Jakóbisiak M. [Immunotherapy of Ehrlich ascites tumor in mice]. Pol Arch Med Wewn 1980; 63:503-9. [PMID: 7413475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
50
|
Mazurek J, Jakóbisiak M. [Immunological aspects of pregnancy]. Ginekol Pol 1974; 45:1215-22. [PMID: 4139050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|